We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

56 hedge funds and large institutions have $216M invested in Adaptimmune Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

14% more funds holding

Funds holding: 49 → 56 (+7)

1.98% more ownership

Funds ownership: 9.36% → 11.33% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less capital invested

Capital invested by funds: $219M → $216M (-$2.84M)

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

Holders
56
Holders Change
+7
Holders Change %
+14.29%
% of All Funds
1.4%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
12
Reduced
13
Closed
3
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
MCMC
Matrix Capital Management Company
New Hampshire
+$45.4M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$2.1M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.51M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$985K
5
EIM
Essex Investment Management
Massachusetts
+$791K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.33M
2
Millennium Management
Millennium Management
New York
-$2.47M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$295K
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$220K
5
Axa
Axa
France
-$170K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$54M – – –
MCMC
2
Matrix Capital Management Company
New Hampshire
$39M +$45.4M +8,692,083 New
Capital World Investors
3
Capital World Investors
California
$30.5M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$23.6M -$5.33M -1,019,900 -16%
O
5
OrbiMed
New York
$8.6M – – –
TCM
6
Tekla Capital Management
Massachusetts
$6.58M – – –
Baillie Gifford & Co
7
Baillie Gifford & Co
United Kingdom
$5.94M +$2.1M +402,324 +44%
QF
8
QVT Financial
New York
$5.66M – – –
HIM
9
Hillhouse Investment Management
Cayman Islands
$5.34M – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$4.8M +$1.51M +288,500 +37%
RSCM
11
Rock Springs Capital Management
Maryland
$3.93M – – –
Axa
12
Axa
France
$3.9M -$170K -32,539 -4%
Fidelity International
13
Fidelity International
Bermuda
$3.38M – – –
Wellington Management Group
14
Wellington Management Group
Massachusetts
$2.54M -$220K -42,080 -7%
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$2.45M +$116K +22,200 +4%
Adage Capital Partners
16
Adage Capital Partners
Massachusetts
$2.06M -$131K -25,000 -5%
AG
17
Artal Group
Luxembourg
$1.35M – – –
Deutsche Bank
18
Deutsche Bank
Germany
$1.13M +$724K +138,519 +122%
A
19
Abingworth
United Kingdom
$1.13M – – –
Millennium Management
20
Millennium Management
New York
$1.11M -$2.47M -472,226 -66%
VIA
21
Vident Investment Advisory
Georgia
$1.09M +$56.9K +10,894 +5%
RG
22
Rathbones Group
United Kingdom
$900K – – –
EIM
23
Essex Investment Management
Massachusetts
$862K +$791K +151,273 +371%
Balyasny Asset Management
24
Balyasny Asset Management
Illinois
$846K +$985K +188,487 New
GIP
25
Granite Investment Partners
California
$838K -$47K -8,993 -5%
1
2 3

ADAP Hedge Fund Activity: Q2 2017 in Review

56 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2017, worth a combined $216M — down 1.3% from $219M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ADAP positions and 3 closed out — a net gain of 7 holders — while 12 added to existing stakes and 13 trimmed.

The largest buyer was Matrix Capital Management Company, opening a new position worth an estimated $45.4M. The largest seller was Fidelity Investments, cutting an estimated $5.33M.

  • 56 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2017, up from 49 in Q1 2017.
  • Funds reported $216M of Adaptimmune Therapeutics stock for Q2 2017, down 1.3% quarter-over-quarter.
  • 10 funds opened new Adaptimmune Therapeutics positions in Q2 2017 and 3 closed out, a net change of +7 holders.
  • The largest Adaptimmune Therapeutics buyer in Q2 2017 was Matrix Capital Management Company, an estimated $45.4M added.
  • The largest Adaptimmune Therapeutics seller in Q2 2017 was Fidelity Investments, an estimated $5.33M sold.

Based on aggregated 13F filings for Q2 2017.